Drug Profile
Tanespimycin nanoemulsion - Biogen Idec
Alternative Names: CNF 101; CNF 1010Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Biogen Idec
- Class Antineoplastics; Benzoquinones; Cytostatic antibiotics; Macrocyclic lactams; Small molecules
- Mechanism of Action Heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic myeloid leukaemia; Solid tumours
Most Recent Events
- 17 May 2007 Discontinued - Phase-I for Chronic myeloid leukaemia in USA (IV-infusion)
- 17 May 2007 Discontinued - Phase-I for Solid tumours in USA (IV-infusion)
- 03 May 2006 Conforma Therapeutics has been acquired and merged into Biogen Idec